About Biocon Our Business Research & Development Biocon's Technology Investors Media Careers CSR
  Press Releases
  Media Stories
  Download Center
  Video Gallery
  Photo Gallery
  Media Contacts

Press Releases

Dr Jeremy Levin Joins Biocon's Board of Directors

Bengaluru, India: January 22, 2015

Biocon Ltd, Asia's premier biotechnology company, announced today that it has inducted Dr. Jeremy M. Levin as an additional independent director to its Board. Dr. Levin is among the 25 most influential people in the biopharmaceutical industry as recognized by FierceBiotech.*

Dr. Levin is currently the Chairman of Ovid Therapeutics Inc., a New York based private company developing novel medicines for orphan diseases of the brain and has deep experience in the global pharmaceuticals and biotechnology industry. He is the former CEO of Teva Pharmaceuticals, the world’s largest generic pharmaceutical Company. Dr Levin played a significant role as a member of the Executive Committee at Bristol-Myers Squibb (BMS) where he had global responsibilities for strategy, alliances and transactions. He led BMS's 'String of Pearls' strategy which helped transform the company pipeline. Dr. Levin has also served as the Head of Global Business Development and Strategic Alliances at Novartis and was Chairman and CEO of Cadus Pharmaceuticals where he successfully took the company public.

Biocon Chairperson and Managing Director, Kiran Mazumdar-Shaw said: "I welcome Jeremy to the Biocon board, he is an exceptional business leader with a deep understanding of the pharmaceutical and biotech industry. His expertise in leading companies, driving business development and company strategy to bring effective treatments to patients worldwide, augurs well for us. We look forward to his valuable contribution towards enabling Biocon make a strong impact on global health."

On his decision to join the Biocon board, Dr. Levin said: "I am extremely pleased to join Biocon which has a unique business model spanning biotech and pharma. I strongly believe a company like Biocon focused on innovation can provide tremendous benefit to patients by developing medicines of the future not only for the developed world but also for the developing nations. Based out of a vibrant democracy such as India Biocon is well placed to balance innovation and access to healthcare."

Dr Levin has the distinction of being the only CEO of a global pharma major to have come from the biotech world. He is the recipient of a number of awards including the Kermode Prize, the Albert Einstein Award for Leadership in Life Sciences, and the Officer's Cross of the Order of Merit of the Republic of Hungary.

Dr Levin has a Doctorate (D.Phil) from the University of Oxford as well as degrees of Bachelor of Medicine and Bachelor of Surgery (MB, BChir) from the University of Cambridge. He has practiced internal medicine at University Hospitals in England, Switzerland and South Africa.

* FierceBiotech is the drug development industry's news monitor, covering biopharma deals, clinical trials, FDA decisions, and more.

About Biocon
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India’s largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global biopharmaceutical enterprise serving customers in over 85 countries, it is committed to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through innovative products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. It has successfully developed and taken a range of novel biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin and analogs from 'Lab to Market'. Some of its key brands are INSUGEN®(rh-insulin), BASALOG® (Glargine), CANMAb™ (Trastuzumab), BIOMAb-EGFR™ (Nimotuzumab) and ALZUMAb ™(Itolizumab), a ‘first in class’ anti-CD6 monoclonal antibody. It has a rich pipeline of biosimilars and novel biologics at various stages of development including a high potential oral insulin.

For further information, please contact:

Media Relations

Seema Ahuja
Phone: +91 080 2808 2808
Email: seema.ahuja@biocon.com

Rumman Ahmed
Phone: +91 080 2808 2808
Email: rumman.ahmed@biocon.com

Investor Relations

Saurabh Paliwal
Phone: +91 95383 80801
Email: saurabh.paliwal@biocon.com

<< Back



Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved